2-Ethoxy-5-bromstyrol | 16602-25-8

• 英文名称: 2-Ethoxy-5-bromstyrol
• 英文别名: 2-Ethoxy-5-bromostyrene；4-bromo-2-ethenyl-1-ethoxybenzene
• CAS: 16602-25-8
• 化学式: C₁₀H₁₁BrO
• 分子量: 227.101
• InChiKey: PMEUHFZYWZEBHZ-UHFFFAOYSA-N

物化性质

• 沸点：
  277.3±28.0 °C(Predicted)
• 密度：
  1.319±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-(5-Bromo-2-ethoxyphenyl)ethan-1-ol 、 potassium hydrogensulfate 以73%的产率得到
  参考文献：
  名称：

  POGOSYAN G. M., XIMIYA NEPREDELN. SOEDIN., (EREVAN), 1979 HO 1, 1959-179

  摘要：

  DOI：

文献信息

• [EN] (3,4-DISUBSTITUTED)PROPANOIC CARBOXYLATES AS S1P (EDG) RECEPTOR AGONISTS<br/>[FR] CARBOXYLATES PROPANOIQUES 3,4-DISUSBSTITUES UTILISES EN TANT QU'AGONISTES DU RECEPTEUR S1P (EDG)
  申请人：MERCK & CO INC

  公开号：WO2005058848A1

  公开（公告）日：2005-06-30

  The present invention encompasses compounds of Formula A: A as well as the pharmaceutically acceptable salts thereof. The compounds are S1P1/Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of treatment or prevention.

  本发明涵盖了化合物A的公式：A以及其药用可接受的盐。这些化合物是S1P1/Edg1受体激动剂，因此通过调节白细胞的运动、在次生淋巴组织中滞留淋巴细胞以及增强血管完整性而具有免疫抑制、抗炎和止血活性。该发明还涉及含有这些化合物的药物组合物以及治疗或预防的方法。
• (3,4-Disubstituted)Propanoic Carboxylates as Sip (Edg) Receptor Agonists
  申请人：Colandrea Vincent J.

  公开号：US20080249093A1

  公开（公告）日：2008-10-09

  The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts thereof. The compounds are S1P 1 /Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of treatment or prevention.

  本发明涵盖以下I式化合物及其药学上可接受的盐。这些化合物是S1P1 / Edg1受体激动剂，因此通过调节白细胞的转移，将淋巴细胞隔离在二级淋巴组织中，并增强血管完整性，具有免疫抑制，抗炎和止血活性。本发明还涉及含有这些化合物的制药组合物和治疗或预防的方法。
• (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
  申请人：Merck & Co., Inc.

  公开号：US07605171B2

  公开（公告）日：2009-10-20

  The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts thereof. The compounds are S1P1/Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of treatment or prevention.

  本发明涵盖公式I的化合物及其药学上可接受的盐。这些化合物是S1P1 / Edg1受体激动剂，因此通过调节白细胞转移，将淋巴细胞隔离在二级淋巴组织中并增强血管完整性，具有免疫抑制、抗炎和止血活性。本发明还涉及含有这种化合物的制药组合物和治疗或预防的方法。
• ORGANOPOLYSILOXANE GRAFT POLYMER
  申请人：Kao Corporation

  公开号：EP2927253A1

  公开（公告）日：2015-10-07

  The present invention relates to an organopolysiloxane graft polymer including an organopolysiloxane segment as a main chain thereof and an unsaturated monomer-derived polymer segment as a side chain thereof, in which a content of the organopolysiloxane segment in the organopolysiloxane graft polymer is not less than 35% by mass and not more than 70% by mass, and the unsaturated monomer-derived polymer segment contains a repeating unit derived from a nonionic unsaturated monomer having a glass transition temperature Tg of 60°C or higher (except for a repeating unit derived from an unsaturated monomer containing an amino group) in an amount of not less than 40% by mass and not more than 90% by mass, and further contains a repeating unit derived from a cationic unsaturated monomer in an amount of not less than 10% by mass and not more than 60% by mass.

  本发明涉及一种有机聚硅氧烷接枝聚合物，包括作为其主链的有机聚硅氧烷段和作为其侧链的不饱和单体衍生聚合物段，其中有机聚硅氧烷段在有机聚硅氧烷接枝聚合物中的含量不低于35%（质量百分比）且不超过70%（质量百分比）、不饱和单体衍生的聚合物段含有由玻璃化转变温度 Tg 为 60°C 或更高的非离子不饱和单体衍生的重复单元（由含有氨基的不饱和单体衍生的重复单元除外），其含量不低于 40%（按质量计）且不超过 90%（按质量计），还含有由阳离子不饱和单体衍生的重复单元，其含量不低于 10%（按质量计）且不超过 60%（按质量计）。
• Responsive microgel and methods related thereto
  申请人：——

  公开号：US20030152623A1

  公开（公告）日：2003-08-14

  A responsive microgel is provided which responds volumetrically and reversibly to a change in one or more aqueous conditions selected from the group consisting of (temperature, pH, and ionic conditions) comprised of an ionizable network of covalently cross-linked homopolymeric ionizable monomers wherein the ionizable network is covalently attached to an amphiphilic copolymer to form a plurality of ‘dangling chains’ and wherein the ‘dangling chains’ of amphiphilic copolymer form immobile micelle-like aggregates in aqueous solution. A responsive microgel is further provided that comprises at least one therapeutic entity and delivers a substantially linear and sustained release of the therapeutic entity under physiological conditions.

  本发明提供了一种响应型微凝胶，该微凝胶可对选自由温度、pH 值和离子条件组成的组中的一种或多种水性条件的变化作出体积上和可逆的响应、和离子条件）组成的共价交联均聚可离子化单体的可离子化网络，其中可离子化网络与两性共聚物共价连接，形成多条 "悬链"，两性共聚物的 "悬链 "在水溶液中形成不动的胶束状聚集体。还提供了一种响应性微凝胶，它包含至少一种治疗实体，并能在生理条件下提供治疗实体的线性和持续释放。